Induction of gene amplification as a gain-of-function phenotype of mutant p53 proteins.

No abstract is available for this paper.

• Publication year

  2002

• Venue

  Cancer Research

• Publication date

  2002-06-01

• Fields of study

  Biology, Medicine

• Identifiers
  PMID 12036943
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification

  2001cited by this paper
• Molecular characterisation of camptothecin-induced mutations at the hprt locus in Chinese hamster cells.

  2001cited by this paper
• Dissociation of DNA binding and in vitro transcriptional activities dependent on the C terminus of P53 proteins.

  2001cited by this paper
• Camptothecin enhances random integration of transfected DNA into the genome of mammalian cells.

  2000cited by this paper
• Rational design of cytotoxic T-cell inhibitors

  2000cited by this paper
• p53: death star.

  2000cited by this paper
• DNA alterations in cancer : genetic and epigenetic changes

  2000cited by this paper
• Human topoisomerase IIalpha and IIbeta interact with the C-terminal region of p53.

  2000cited by this paper
• Conversion of Topoisomerase I Cleavage Complexes on the Leading Strand of Ribosomal DNA into 5′-Phosphorylated DNA Double-Strand Breaks by Replication Runoff

  2000cited by this paper
• p53 dependence of topoisomerase I recruitment in vivo.

  2000cited by this paper
• Gain-of-function mutations in the tumor suppressor gene p53.

  2000cited by this paper
• An immunodominant epitope on DNA topoisomerase I is conformational in nature: heterogeneity in its recognition by systemic sclerosis sera.

  1999cited by this paper
• Radiation-induced mutations at the autosomal thymidine kinase locus are not elevated in p53-null cells.

  1999cited by this paper
• The interaction between p53 and DNA topoisomerase I is regulated differently in cells with wild-type and mutant p53.

  1999cited by this paper
• C-myc overexpression and p53 loss cooperate to promote genomic instability

  1999cited by this paper
• 1q23 gain is associated with progressive neuroblastoma resistant to aggressive treatment.

  1999cited by this paper
• Mechanism of action of eukaryotic DNA topoisomerase I and drugs targeted to the enzyme.

  1998cited by this paper
• Expression of a p53 mutant in the epidermis of transgenic mice accelerates chemical carcinogenesis

  1998cited by this paper
• Analysis of centrosome abnormalities and angiogenesis in epidermal‐targeted p53172H mutant and p53‐knockout mice after chemical carcinogenesis: Evidence for a gain of function

  1998cited by this paper
• Chromosomal amplification is associated with cisplatin resistance of human male germ cell tumors.

  1998cited by this paper
• MYC Abrogates p53-Mediated Cell Cycle Arrest in N-(Phosphonacetyl)-l-Aspartate-Treated Cells, Permitting CAD Gene Amplification

  1998cited by this paper
• The complexity of p53 modulation: emerging patterns from divergent signals.

  1998cited by this paper
• Wild-type and mutant forms of p53 activate human topoisomerase I: a possible mechanism for gain of function in mutants.

  1998influential reference
• DNA copy number amplifications in human neoplasms: review of comparative genomic hybridization studies.

  1998cited by this paper
• Genomic instability and apoptosis are frequent in p53 deficient young mice

  1997cited by this paper
• Genetic instability in colorectal cancers

  1997cited by this paper
• Binding of wild-type p53 by topoisomerase II and overexpression of topoisomerase II in human hepatocellular carcinoma.

  1997cited by this paper
• Trapping of Mammalian Topoisomerase I and Recombinations Induced by Damaged DNA Containing Nicks or Gaps

  1997cited by this paper
• Topoisomerase I enhances TFIID-TFIIA complex assembly during activation of transcription.

  1997cited by this paper
• Abnormal Centrosome Amplification in the Absence of p53

  1996cited by this paper
• The single-stranded DNA end binding site of p53 coincides with the C-terminal regulatory region.

  1996cited by this paper
• Modulation of DNA topoisomerase I activity by p53.

  1996cited by this paper
• c-Myc overexpression associated DHFR gene amplification in hamster, rat, mouse and human cell lines.

  1996cited by this paper
• A Role for Endothelial NO Synthase in LTP Revealed by Adenovirus-Mediated Inhibition and Rescue

  1996cited by this paper
• Paradoxical tumor inhibitory effect of p53 loss in transgenic mice expressing epidermal-targeted v-rasHa, v-fos, or human transforming growth factor alpha.

  1996cited by this paper
• Topoisomerase Poisons: Harnessing the Dark Side of Enzyme Mechanism (*)

  1995cited by this paper
• Spontaneous and ionizing radiation-induced chromosomal abnormalities in p53-deficient mice.

  1995cited by this paper
• Mutagenic activity of topoisomerase I inhibitors

  1995cited by this paper
• Characterization of intra- and intermolecular DNA ligation mediated by eukaryotic topoisomerase I. Role of bipartite DNA interaction in the ligation process.

  1994cited by this paper
• Gain-of-function mutations of the p53 gene induce lymphohematopoietic metastatic potential and tissue invasiveness.

  1994cited by this paper
• p53‐catalyzed annealing of complementary single‐stranded nucleic acids.

  1993cited by this paper
• Identification of human DNA topoisomerase I as a cofactor for activator-dependent transcription by RNA polymerase II.

  1993cited by this paper
• A proteolytic fragment from the central region of p53 has marked sequence-specific DNA-binding activity when generated from wild-type but not from oncogenic mutant p53 protein.

  1993cited by this paper
• Gain of function mutations in p53

  1993cited by this paper
• Oncogenic forms of p53 inhibit p53-regulated gene expression.

  1992cited by this paper
• Tight control of gene expression in mammalian cells by tetracycline-responsive promoters.

  1992cited by this paper
• Altered cell cycle arrest and gene amplification potential accompany loss of wild-type p53.

  1992cited by this paper
• Mutant p53 proteins bind DNA abnormally in vitro.

  1991cited by this paper
• p53 mutations in human cancers.

  1991cited by this paper
• Alterations in tumor development in vivo mediated by expression of wild type or mutant p53 proteins.

  1991cited by this paper
• p53 gene mutations occur in combination with 17p allelic deletions as late events in colorectal tumorigenesis.

  1990cited by this paper
• Genotoxicity of inhibitors of DNA topoisomerases I (camptothecin) and II (m-AMSA) in vivo and in vitro.

  1990cited by this paper
• Spontaneous abnormalities in normal fibroblasts from patients with Li-Fraumeni cancer syndrome: aneuploidy and immortalization.

  1990cited by this paper
• Regulation of the level of the oncoprotein p53 in non-transformed and transformed cells.

  1990cited by this paper
• Mutations in the p53 gene occur in diverse human tumour types

  1989cited by this paper
• Expression of human DNA topoisomerase I in yeast cells lacking yeast DNA topoisomerase I: restoration of sensitivity of the cells to the antitumor drug camptothecin.

  1989cited by this paper
• Chromosome 17 deletions and p53 gene mutations in colorectal carcinomas.

  1989cited by this paper
• Induction of chromosomal aberrations and SCE by camptothecin, an inhibitor of mammalian topoisomerase I.

  1989cited by this paper
• Meth A fibrosarcoma cells express two transforming mutant p53 species.

  1988cited by this paper
• Activating mutations for transformation by p53 produce a gene product that forms an hsc70-p53 complex with an altered half-life

  1988cited by this paper
• Structure of DNA formed in the first step of CAD gene amplification.

  1986cited by this paper
• Reconstitution of p53 expression in a nonproducer Ab-MuLV-transformed cell line by transfection of a functional p53 gene.

  1984cited by this paper
• Gene amplification causes overproduction of the first three enzymes of UMP synthesis in N-(phosphonacetyl)-L-aspartate-resistant hamster cells.

  1979cited by this paper

• TP53 gain-of-function mutations promote osimertinib resistance via TNF-α–NF-κB signaling in EGFR-mutated lung cancer

  2024cites this paper
• The Role of TP53 Mutations in EGFR-Mutated Non-Small-Cell Lung Cancer: Clinical Significance and Implications for Therapy

  2022cites this paper
• Mutant p53 in cancer: from molecular mechanism to therapeutic modulation

  2022cites this paper
• The oncogenic potential of a mutant TP53 gene explored in two spontaneous lung cancer mice models

  2020cites this paper
• OVER KANSERİ HÜCRELERİNDE PRİMA-1 Met TEDAVİSİNE YANIT OLARAK DEĞİŞEN miRNA EKSPRESYON ANALİZİ

  2020cites this paper
• Molecular Biology of Osteosarcoma

  2020cites this paper
• Applications of Recombinant Adenovirus-p53 Gene Therapy for Cancers in the Clinic in China.

  2020cites this paper
• MODELING CANCER USING LI-FRAUMENI SYNDROME PATIENT-DERIVED INDUCED PLURIPOTENT STEM CELLS

  2019cites this paper
• Therapeutic targeting of p53: all mutants are equal, but some mutants are more equal than others

  2018cites this paper
• Li-Fraumeni Syndrome Disease Model: A Platform to Develop Precision Cancer Therapy Targeting Oncogenic p53.

  2017cites this paper
• Role of Pkc Delta in Uv Radiation Dna Damage Repair

  2016cites this paper
• Comparison of Effects of p53 Null and Gain-of-Function Mutations on Salivary Tumors in MMTV-Hras Transgenic Mice

  2015cites this paper
• The Contrived Mutant p53 Oncogene – Beyond Loss of Functions

  2015cites this paper
• The Role of microRNAs in the Regulation of Apoptosis in Lung Cancer and Its Application in Cancer Treatment

  2014cites this paper
• p53: its mutations and their impact on transcription.

  2014cites this paper
• Mutant p53 in Cancer: New Functions and Therapeutic Opportunities

  2014cites this paper
• Cooperation of p53 mutations with other oncogenic alterations in cancer.

  2014cites this paper
• Mutant p53 Cooperates with Knockdown of Endogenous Wild-Type p53 to Disrupt Tubulogenesis in Madin-Darby Canine Kidney Cells

  2013cites this paper
• Preferential Binding of Hot Spot Mutant p53 Proteins to Supercoiled DNA In Vitro and in Cells

  2013cites this paper
• Assessment and modulation of chemoresistance by different sub-groups of chemosensitizers in a NHL cell line model

  2012cites this paper
• DNA Topoisomerase I and Illegitimate Recombination

  2012cites this paper
• Mutant p53: one name, many proteins.

  2012cites this paper
• Links between mutant p53 and genomic instability

  2012cites this paper
• p53 mutants induce transcription of NF-κB2 in H1299 cells through CBP and STAT binding on the NF-κB2 promoter and gain of function activity.

  2012cites this paper
• Prognostic Significance of p53 Protein and X-ray Repair Cross-Complementing Protein 1 in Non-Small Cell Lung Cancer

  2011cites this paper
• Mutant p53 oncogenic functions are sustained by Plk2 kinase through an autoregulatory feedback loop

  2011cites this paper
• Mutant p53 gain-of-function in cancer.

  2010cites this paper
• MicroRNA‐34a is an important component of PRIMA‐1‐induced apoptotic network in human lung cancer cells

  2010cites this paper
• Extrachromosomal Double Minutes and Chromosomal Homogeneously Staining Regions as Probes for Chromosome Research

  2009cites this paper
• p53: balancing tumour suppression and implications for the clinic.

  2009cites this paper
• Expression of a Mutant p53 Results in an Age-Related Demographic Shift in Spontaneous Lung Tumor Formation in Transgenic Mice

  2009cites this paper
• Mutant p53 gain of oncogenic function: in vivo evidence, mechanism of action and its clinical implications.

  2009cites this paper
• Dissecting the role of p53 phosphorylation in homologous recombination provides new clues for gain-of-function mutants

  2008influential citation
• Lung specific expression of a human mutant p53 affects cell proliferation in transgenic mice

  2008cites this paper
• Contribution of the DNA binding domain of p53 to regulation of its stability

  2008cites this paper
• P53 expression is associated with malignant potential in xenograft tissues of a fibrosarcoma mouse model.

  2007cites this paper
• Cancer-derived p53 mutants suppress p53-target gene expression—potential mechanism for gain of function of mutant p53

  2007cites this paper
• Cancer-derived p 53 mutants suppress p 53-target gene expression — potential mechanism for gain of function of mutant p 53

  2007cites this paper
• Transcription regulation by mutant p53

  2007cites this paper
• Mutant p53 protects cells from 12-O-tetradecanoylphorbol-13-acetate-induced death by attenuating activating transcription factor 3 induction.

  2006cites this paper
• Gain of function of mutant p53: the mutant p53/NF-Y protein complex reveals an aberrant transcriptional mechanism of cell cycle regulation.

  2006cites this paper
• Poly(ADP-RIBOSE) polymerase-1 (Parp-1) antagonizes topoisomerase I-dependent recombination stimulation by P53

  2006cites this paper
• Poly ( ADP-RIBOSE ) polymerase-1 ( Parp-1 ) antagonizes topoisomerase I-dependent recombination stimulation by P 53

  2006cites this paper
• Alterations in Mitochondrial and Apoptosis-regulating Gene Expression in Photodynamic Therapy-resistant Variants of HT29 Colon Carcinoma Cells¶

  2005influential citation
• Mutant p53 proteins bind DNA in a DNA structure-selective mode

  2005cites this paper
• When, where and how the bridge breaks: anaphase bridge breakage plays a crucial role in gene amplification and HSR generation.

  2005cites this paper
• Alterations in Mitochondrial and Apoptosis‐regulating Gene Expression in Photodynamic Therapy‐resistant Variants of HT29 Colon Carcinoma Cells ¶

  2005cites this paper
• The Oncogenic Activity of p53 Mutants

  2005cites this paper
• The p53 Tumor Suppressor Pathway and Cancer

  2005cites this paper
• Trinucleotide Repeats (TNRs): DNA-Bindungssubstrate für Wildtyp und mutiertes p53 und Modulatoren der p53-abhängigen Transkription

  2005cites this paper
• MODULATION OF GENE EXPRESSION BY TUMOR-DERIVED MUTANT p53. ROLE OF TRANSACTIVATION IN GAIN-OF-FUNCTION.

  2005cites this paper
• Transcription Factors

  2004cites this paper
• The p53 Transcription Factor as Therapeutic Target in Cancer

  2004cites this paper
• Recombination at chromosomal sequences involved in leukaemogenic rearrangements is differentially regulated by p53.

  2004cites this paper
• Funktionelle Interaktionen zwischen Wildtyp-p53, Rad51 und Poly-ADP-Phosphoribosyl-Transferase bei der Kontrolle von DNA-Rekombinationsprozessen

  2004cites this paper
• Molecular alterations associated with cyclin d1 overexpression in endometrial cancer

  2004cites this paper
• Cell type‐specific regulation of calmodulin 2 expression by mutant p53

  2004cites this paper
• No anti-apoptotic effects of single copies of mutant p53 genes in drug-treated tumor cells

  2004cites this paper
• Constitutive and DNA damage inducible activation of pig3 and MDM2 genes by tumor-derived p53 mutant C277Y.

  2004cites this paper
• Selection pressures of TP53 mutation and microenvironmental location influence epidermal growth factor receptor gene amplification in human glioblastomas.

  2003cites this paper
• Replication of an E1B 55-Kilodalton Protein-Deficient Adenovirus (ONYX-015) Is Restored by Gain-of-Function Rather than Loss-of-Function p53 Mutants

  2003cites this paper
• p53 family members and chemoresistance in cancer: what we know and what we need to know.

  2003cites this paper
• Glioblastomas Gene Amplification in Human Factor Receptor Epidermal Growth Microenvironmental Location Influence Mutation and TP 53 Selection Pressures of Updated

  2003cites this paper
• Replication of an E 1 B 55-Kilodalton Protein-Deficient Adenovirus ( ONYX-015 ) Is Restored by Gain-of-Function Rather than Loss-of-Function p 53 Mutants

  2003cites this paper
• Human topoisomerase I cleavage complexes are repaired by a p53-stimulated recombination-like reaction in vitro.

  2002cites this paper